23 Jul, 2026
According to Straits Research, The global cancer treatment market size was valued at $282.28 billion in 2025 and is projected to grow from $308.44 billion in 2026 to $643.50 billion by 2034 at a CAGR of 9.63% during the forecast period 2026-2034.
The market growth is attributed to the rising burden of cancer worldwide, expanding therapeutic innovations, rapid approval and adoption of novel therapies, and improved access to precision diagnostics. In addition, there exists a persistent unmet demand in oncology attributable to the rising incidence of cancer diagnoses. This draws cash inflows from both private investors and the government. Pharmaceutical conglomerates are expediting their pipelines via strategic acquisitions, while the government significantly invests in infrastructure and early-stage scientific research. In July 2025, Merck KGaA finalised the acquisition of SpringWorks Therapeutics, a biopharmaceutical firm specialising in severe rare diseases and cancer, for USD 3.4 billion. This dual approach mitigates development risks and accelerates commercialization timelines, hence ensuring continuous market growth. Moreover, hospitals now use simpler, faster tests on tumors and blood to find who will benefit from which medicine. When these tests spot the right signal or gene change, doctors can start the most effective drug sooner, often in earlier stages. Health systems are covering these tests more often, and regulators approve new drugs together with their tests, which speeds real-world use. This means more patients qualify, start treatment earlier, and stay on therapy longer, lifting demand for checkpoint drugs, targeted pills, antibody drug conjugates, and even cell and gene therapies across the cancer treatment market.
sales@straitsresearch.com